| Title | Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. | | Author(s) | Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Musher DM | | Institution | Section of Infectious Diseases, Baylor College of Medicine, One Baylor Plaza, BCM 286, N1319, Houston, TX 77030, USA. | | Source | J Infect 2008 Jun 16. | | Abstract | OBJECTIVES: Hematogenous vertebral osteomyelitis is caused predominantly by Staphylococcus aureus. The rise in incidence of methicillin-resistant S. aureus (MRSA) has complicated the treatment of this infection. Our objective was to evaluate therapeutic outcomes for S. aureus vertebral osteomyelitis in a setting of high MRSA prevalence.
METHODS: We conducted a retrospective chart review of all patients who presented with S. aureus vertebral osteomyelitis over a 7-year period at 2 tertiary care hospitals in Houston, TX, USA.
RESULTS: Thirty-five patients were identified who received >/=2-week course of parenteral antibiotics and had a follow-up period of at least 12 months post-therapy. MRSA was responsible for 20 (57%) cases. Mean duration of total antibiotic therapy was 61.4 days. The overall relapse rate was 14%. At 12 months post-therapy, 86% patients were cured. The one factor significantly associated with relapse was presence of undrained abscesses (p=0.04).
CONCLUSIONS: When the mean duration of effective antibiotic therapy was 60 days, cure rates for S. aureus vertebral osteomyelitis exceeded 80%. Drainage of all associated abscesses correlated with a significantly higher rate of cure. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 18562009 |
|
